Accelerated Pharma (Accelerated Pharma) Cash Flow from Others : $0.49 Mil (TTM As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Cash Flow from Others?

Accelerated Pharma's cash flow from others for the three months ended in Mar. 2017 was $0.25 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2017 was $0.49 Mil.

Accelerated Pharma Cash Flow from Others Historical Data

The historical data trend for Accelerated Pharma's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Cash Flow from Others Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Cash Flow from Others

0.37

0.44

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Cash Flow from Others	Get a 7-Day Free Trial			0.20	0.07	0.12	0.05	0.25

Accelerated Pharma Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.49 Mil.

Accelerated Pharma Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines